Diagnostic alpha defensin 1 (α-defensin 1) antibodies (anti-alpha defensin 1, anti-α-defensin 1) and antigens (recombinant alpha defensin 1 (α-defensin 1) protein) for Inflammation/autoimmune/inflammatory disease α-defensin 1 detection in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.
Cat:GMP-h-a-defensin-1
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Genemedi produces core diagnostic ingredients for test of Inflammation/autoimmune/inflammatory disease (Prosthetic joint infection (PJI)) and related syndrome. GeneMedi offers paired diagnostics grade alpha defensin 1 (α-defensin 1) antibodies (monoclonal antibody, mab) and antigens for Inflammation/autoimmune/inflammatory disease (Prosthetic joint infection (PJI)) rapid test kit of alpha defensin 1 (α-defensin 1) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Inflammation/autoimmune/inflammatory disease (Prosthetic joint infection (PJI) ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.
Genemedi produces core diagnostic ingredients for test of Inflammation/autoimmune/inflammatory disease (Prosthetic joint infection (PJI)) and related syndrome. GeneMedi offers paired diagnostics grade alpha defensin 1 (α-defensin 1) antibodies (monoclonal antibody, mab) and antigens for Inflammation/autoimmune/inflammatory disease (Prosthetic joint infection (PJI)) rapid test kit of alpha defensin 1 (α-defensin 1) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Inflammation/autoimmune/inflammatory disease (Prosthetic joint infection (PJI) ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.Alpha defensins are a family of mammalian defensin peptides of the alpha subfamily. Prosthetic joint infection (PJI) management is not standardized worldwide. Diagnosis of PJI remains challenging because the clinical signs and symptoms and elevation of systemic biomarkers (C-reactive protein, erythrocyte sedimentation rate) may be unclear. Synovial biomarkers have shown encouraging results and they should be used as diagnostic adjuncts to synovial white cell count and culture bacteriology. Synovial leukocyte esterase (LE) and synovial C-reactive protein (CRP) have been evaluated as good screening measures; however, the most promising synovial fluid biomarker in terms of sensitivity and specificity for PJI seems to be alpha defensin (AD). alpha defensin lateral flow test could have its place in ruling in a suspected PJI intraoperatively because of its high specificity and rapid results.
Product Description
Cat No. of Pruducts
GMP-h-a-defensin-1-Ag01
Product Name
Recombinant human Human α-defensin 1 Protein
Target
alpha defensin 1
Alias of Target/Biomarker
Expression platform
synthesized
Isotypes
Peptide Antigen
Bioactivity validation
alpha defensin 1 (α-defensin 1) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in α-defensin 1 level test of Inflammation/autoimmune/inflammatory disease (Prosthetic joint infection (PJI)) and related syndrome evaluation
Tag
NA
Products description
Recombinant human Human α-defensin 1 Protein was expressed in E.coli -based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Reconized/Reactive Species
Human
Purity
Purity: ≥95% (HPLC)
Application
Standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at -20℃ to -84℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Previous slide
Next slide
Cat No. of Pruducts
GMP-h-a-defensin-1-Ab01,GMP-h-a-defensin-1-Ab02
Product Name
Anti-human Human α-defensin 1 mouse monoclonal antibody (mAb)
Target
alpha defensin 1
Alias of Target/Biomarker
DEFA1, DEF1, DEFA2, HNP-1, HP-1, HP1, MRS
Expression platform
Hybridoma
Isotypes
Mouse IgG
Bioactivity validation
Human alpha defensin 1 (α-defensin 1) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other alpha defensin 1 (α-defensin 1) antibodies in α-defensin 1 level test of Inflammation/autoimmune/inflammatory disease (Prosthetic joint infection (PJI)) and related syndrome evaluation.
Tag
mFc
Products description
Anti-human Human α-defensin 1 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other alpha defensin 1 (α-defensin 1) antibodies.
Reconized/Reactive Species
Human
Purity
Purity: ≥95% (SDS-PAGE)
Application
ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at -20℃ to -85℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1
Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
